Viral Dynamics and Pharmacokinetics of Abacavir and Tenofovir

• Sponsor: University of California, San Diego (Other)
• Overall Status: Completed
• CT.gov ID: NCT00214890
• Collaborator: Universitywide AIDS Research Program (Other), GlaxoSmithKline (Industry), University of California, Irvine (Other), University of California, Los Angeles (Other), University of Southern California (Other), Santa Clara Valley Medical Center (Other)
• Enrollment: 21
• Locations: 5
• Arms: 2
• Actual Duration (Months): 64.6
• Patients Per Site: 4.2
• Patients Per Site Per Month: 0.1

Study Details

Study Description

Brief Summary

Once-daily nucleotide/nucleoside reverse transcriptase inhibitor (NtRTI/NRTI) combinations form the backbone of many regimens. Although efficacy data exists between tenofovir and the pyrimidine analogues (i.e. lamivudine and emtricitabine), recent clinical data suggests a potential interaction between tenofovir and purine analogs (i.e. abacavir and didanosine).

Specific Aim 1: To evaluate the impact of an acyclic nucleoside phosphonate, tenofovir (TDF), on the intracellular metabolism of a purine nucleoside analog, abacavir (ABC), as a determinant of the antiviral potency of this nucleotide/nucleoside reverse transcriptase inhibitor (NtRTI/NRTI) combination.

• Hypothesis #1: ABC and TDF dosed together will have reduced antiviral activity, as measured by early plasma HIV RNA decay kinetics, than the drugs given alone.

• Hypothesis #2: ABC dosed with TDF will have reduced intracellular concentrations, as measured by the ratio of carbovir triphosphate (active metabolite of ABC) to deoxyguanosine triphosphate (endogenous nucleotide), compared to ABC given alone.

Condition or Disease	Intervention/Treatment	Phase
HIV Infections	Drug: Tenofovir; Drug: Abacavir	Phase 2

Detailed Description

The primary objectives of this study are to compare the virologic potency and pharmacology of TDF and ABC alone and in combination. Since it is not feasible or ethical to give mono or dual-therapy with these agents for prolonged intervals, this project was designed to take advantage of a short term drug exposure. The study performs intensive lab monitoring with a cross-over design to compare short courses of monotherapy and dual-therapy. This is an open-labeled study of a dual NRTI/NtRTI combination, ABC + TDF, compared to ABC and TDF monotherapy administered for 7 days. A screening genotype will be done to confirm that there are no resistance-associated mutations at baseline. Each subject will then be randomized to a 7-day sequence of monotherapy (ABC or TDF), and four measurements for plasma HIV RNA will be done to calculate the slope of the phase one viral decay. Prior to initiation of nucleoside analogues, PBMCs will be collected to measure baseline expression of nucleoside transport enzymes via RT-PCR and Western blot analysis. On days 7 and 8, serial blood specimens will be collected for plasma and intracellular levels of TDF and ABC. The monotherapy sequence will be followed by a 35-day washout period.

After the washout (day 42), subjects will initiate the dual NRTI/NtRTI therapy sequence for an additional 7 days. During dual NRTI/NtRTI therapy, again, four measurements for HIV RNA will be done to calculate the slope of the phase one viral decay. On day 48 and 49, serial plasma and intracellular levels of ABC + TDF will be evaluated. On Day 49 a second HIV genotype will be performed in real time. On day 49, after the second 7-day sequence, all subjects will receive EFV in addition to the ABC + TDF combination for 14 days. Afterwards, a second sample of PBMCs will be collected to evaluate for a potential induction or suppression of nucleoside transport enzymes. Since the long-term efficacy of the TDF + ABC nucleoside backbone is not yet known, TDF will be discontinued (day 63) and 3TC will be substituted. Subjects will then continue on the HAART portion of the study for an additional 46 weeks of EFV + ABC + 3TC.

Study Design

• Study Type: Interventional
• Actual Enrollment: 21 participants
• Allocation: Randomized
• Intervention Model: Crossover Assignment
• Intervention Model Description: This is a comparative, open-labeled study of a dual NRTI regimen, TDF + ABC, compared to ABC and TDF monotherapy administered for 7 days. Each patient will be randomized to a 7-day sequence of either ABC or TDF once-daily followed by a 35-day washout period. After completion of the monotherapy sequence all patients will then receive dual NRTI therapy of TDF + ABC for an additional 7 days. After completion of the dual NRTI sequence patients will enter the HAART treatment stage with the addition of EFV and continue on a once-daily regimen of EFV + ABC + TDF for an additional 14 days. At day 63, TDF will be stopped and 3TC will be substituted. Patients will then continue on a once-daily regimen of EFV + ABC + 3TC for an additional 46 weeks.This is a comparative, open-labeled study of a dual NRTI regimen, TDF + ABC, compared to ABC and TDF monotherapy administered for 7 days. Each patient will be randomized to a 7-day sequence of either ABC or TDF once-daily followed by a 35-day washout period. After completion of the monotherapy sequence all patients will then receive dual NRTI therapy of TDF + ABC for an additional 7 days. After completion of the dual NRTI sequence patients will enter the HAART treatment stage with the addition of EFV and continue on a once-daily regimen of EFV + ABC + TDF for an additional 14 days. At day 63, TDF will be stopped and 3TC will be substituted. Patients will then continue on a once-daily regimen of EFV + ABC + 3TC for an additional 46 weeks.
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: CCTG584: Viral Dynamics and Pharmacokinetics of Tenofovir and Abacavir Monotherapy Versus the Combination Therapy of TDF-ABC in HIV-Infected Treatment Naive Patients
• Actual Study Start Date: Dec 7, 2004
• Actual Primary Completion Date: Jun 26, 2008
• Actual Study Completion Date: Apr 27, 2010

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: Tenofovir As part of this study visit, you participants will be assigned by chance to receive either TDF alone or ABC alone	Drug: Tenofovir; 300 mg once daily; Other Names: (TDF)
Active Comparator: Abacavir As part of this study visit, you participants will be assigned by chance to receive either TDF alone or ABC alone	Drug: Abacavir; 600 mg once daily; Other Names: (ABC, Ziagen)

Outcome Measures

Primary Outcome Measures

1. Change in Short-term Virologic Response [49 days]

   Relative potencies of two monotherapy regimens (TDF alone vs. ABC alone) compared to the dual NRTI regimen of TDF+ABC as assessed by the short-term virologic response. (Change in HIV RNA copies/mL at baseline and day 7 for monotherapy, baseline and day 49 for dual therapy.)

2. Compare the Plasma Data of the Two Monotherapy Regimens to the Dual NRTI Regimen [49 days]

   At day 49 of Sequence 2 a 24-hour post dose plasma sample should be collected and processed. All 7 samples from the sparse PK (time 0, 30-min, 1-hr, 2-hr, 3-hr, 6-hr and 24-hr post dose) should be sent overnight to appropriate off-site lab for analysis. Since the patient is on dual therapy and the each drug is measured in separate labs each PBMC samples should be split at each time-point with half of the samples shipped to Gilead and half shipped to USC (two separate shipments). ALL plasma samples should be sent to USC. Since samples have to be split we will need to collect double the blood for the intracellular (PBMC) PK: Blood volume (PBMC-plasma): 40 mL - each draw Blood volume (plasma only): 3 mL - each draw Blood volume: 169 mL- over 2 days Plasma NRTI and intracellular ddNTP concentrations were measured 7 days after treatment with ABC or TDF alone and were compared to levels obtained after 7 days of treatment with both drugs

3. Compare the Intracellular Pharmacokinetic (PK) Data of the Two Monotherapy Regimens to the Dual NRTI Regimen [49 days]

   At day 49 of Sequence 2 a 24-hour post dose intracellular (PBMC) should be collected and processed. All 7 samples from the sparse PK (time 0, 30-min, 1-hr, 2-hr, 3-hr, 6-hr and 24-hr post dose) should be sent overnight to appropriate off-site lab for analysis. Since the patient is on dual therapy and the each drug is measured in separate labs each PBMC samples should be split at each time-point with half of the samples shipped to Gilead and half shipped to USC (two separate shipments). ALL intracellular (PBMC) samples should be sent to USC. Since samples have to be split we will need to collect double the blood for the intracellular (PBMC) PK: Blood volume (PBMC-plasma): 40 mL - each draw Blood volume (plasma only): 3 mL - each draw Blood volume: 169 mL- over 2 days Intracellular ddNTP concentrations were measured after 7 days on monotherapy and after 7 days on dual therapy

Secondary Outcome Measures

1. Evaluate Change in Cellular Regulatory Enzymes Involved With Nucleoside Analogue Transport Across Cell Membranes as Assessed by RT-PCR of Specific mRNA Transcripts [Day 1 and Day 63]

   At day 1 and day 63 a PBMC sample for RT-PCR of nucleoside analogue transport enzymes (enzymes for efflux, influx) will be collected. The day 1 specimen should be stored and sent with day 8 PK specimens to USC. Day 63 specimen should be sent to USC after collection and processing. Blood volume: 20 mL Blood volume: 20 mL

2. Determine Total Number of NRTI-associated Mutations After 7 Days of ABC or TDF Monotherapy or After 7 Days of Dual NRTI Therapy With ABC + TDF [7 days]

   Subjects will be randomized to either TDF or ABC PO route for 7 days, which involves a fixed number of subjects. A sample size of 20 subjects (10 ABC and 10 TDF monotherapy and 20 ABC+TDF dual-therapy in HIV-positive patients). We determined the count of NRTI-associated mutations that emerged after 7 days of ABC or TDF monotherapy or after 7 days of dual NRTI therapy with ABC + TDF.

3. Compare the Relative Viral Potency of TDF Monotherapy Versus ABC Monotherapy [Baseline and day 7]

   Eligible patients will be randomized into two monotherapy arms (TDF and ABC) for a short (one week) viral dynamics and pharmacokinetics evaluation to determine their potency. After a one-month washout period, all patients will start a dual-therapy of ABC+TDF. Viral dynamics and pharmacokinetics of the dual-therapy will be evaluated during the first week of the treatment. EFV will be added to the regimen after one week of the dual-therapy administered. Relative potencies of two monotherapy regimens (TDF alone vs. ABC alone) assessed by the short-term virologic response. (Change in HIV RNA copies/mL at baseline and day 7 for monotherapy)

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

1. HIV-1 infection, as documented by any licensed ELISA test kit and confirmed by Western blot at any time prior to study entry. HIV-1 culture, HIV-1 antigen, plasma HIV-1 RNA, or a second antibody test by a method other than ELISA is acceptable as an alternative confirmatory test.

2. Antiretroviral naïve defined as no prior therapy.

3. CD4+ cell count > than 200 cells/ mm3 determined by site clinical laboratory within 90 days of screening.

4. HIV-1 RNA level > 5000 copies/mL obtained by site clinical laboratory within 90 days of screening.

5. Laboratory values obtained by screening laboratories within 30 days of entry:

• Absolute neutrophil count (ANC) ≥ 750/mm3.

• Hemoglobin ≥ 8.0 g/dL.

• Platelet count ≥ 50,000/mm3.

• Calculated creatinine clearance (CrCl) > 50 mL/min as estimated by the

• AST (SGOT), ALT (SGPT), and alkaline phosphatase ≤ 5 x ULN.

• Total bilirubin ≤ 2.5 x ULN.

1. Negative serum or urine pregnancy test within 30 days of study entry.

2. Karnofsky performance score ≥ 70.

3. Men and women age ≥ 18 years.

4. Ability and willingness of subject to give written informed consent.

Exclusion Criteria:

1. Any NRTI or NNRTI-associated resistance mutations as defined by the updated International AIDS Society-USA (IAS-USA) mutation list.

2. Pregnancy and breast-feeding.

3. Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements.

4. Urgent need to initiate antiretroviral therapy, as determined by the patient's primary provider.

5. Serious illness (requiring systemic treatment and/or hospitalization) until subject either completes therapy or is clinically stable on therapy, in the opinion of the investigator, for at least 14 days prior to study entry.

6. Use of any immunomodulator, HIV vaccine, or investigational therapy within 30 days of study entry.

7. Use of human growth hormone within 30 days prior to study entry.

8. Initiation of testosterone or anabolic steroids within 30 days prior to study entry. (Exception: Chronic replacement dosages in patient's with diagnosed hypogonadism is allowed)

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	UCI	Irvine	California	United States	92668
2	USC	Los Angeles	California	United States	90033
3	University of California San Diego	San Diego	California	United States	92103
4	Santa Clara Valley Medical Center	San Jose	California	United States	95128
5	Harbor-UCLA Medical Center	Torrance	California	United States	90502

Sponsors and Collaborators

• University of California, San Diego
• Universitywide AIDS Research Program
• GlaxoSmithKline
• University of California, Irvine
• University of California, Los Angeles
• University of Southern California
• Santa Clara Valley Medical Center

Investigators

• Study Chair: Richard H Haubrich, MD, University California San Diego
• Principal Investigator: Miguel A Goicoechea, MD, University California San Diego

Study Documents (Full-Text)

• Study Protocol and Statistical Analysis Plan - Sep 1, 2004

More Information

Additional Information:

• CCTG homepage

Publications

None provided.

• Responsible Party: University of California, San Diego
• ClinicalTrials.gov Identifier: NCT00214890
• Other Study ID Numbers: CCTG584
• First Posted: Sep 22, 2005
• Last Update Posted: Sep 24, 2021
• Last Verified: Sep 1, 2021

• Keywords provided by University of California, San Diego: HIV; nucleoside pharmacology; drug-drug interaction; Treatment Naive; Drug resistance; Drug pharmacokinetics
• Additional relevant MeSH terms: HIV Infections; Tenofovir; Abacavir

Study Results

Participant Flow

Arm/Group Title	Tenofovir	Abacavir
Arm/Group Description	Monotherapy tenofovir (300mg) for 7 days followed by a 35-day washout period then 7 days of ABC + TDF dual therapy	Monotherapy abacavir (600mg) for 7 days followed by a 35-day washout period then 7 days of ABC + TDF dual therapy
Period Title: Overall Study
STARTED	10	11
COMPLETED	10	11
NOT COMPLETED	0	0

Baseline Characteristics

Arm/Group Title	Tenofovir	Abacavir	Total
Arm/Group Description	Monotherapy tenofovir (300mg) for 7 days followed by a 35-day washout period then 7 days of ABC + TDF dual therapy	Monotherapy abacavir (600mg) for 7 days followed by a 35-day washout period then 7 days of ABC + TDF dual therapy	Total of all reporting groups
Overall Participants	10	11	21
Age (years) [Median (Full Range) ]
Median (Full Range) [years]	NA	NA	37
Sex: Female, Male (Count of Participants)
Female	4 40%	2 18.2%	6 28.6%
Male	6 60%	9 81.8%	15 71.4%
Race/Ethnicity, Customized (Count of Participants)
White	6 60%	8 72.7%	14 66.7%
Black	0 0%	1 9.1%	1 4.8%
Asian	1 10%	1 9.1%	2 9.5%
American Indian	2 20%	0 0%	2 9.5%
Other or unknown	1 10%	1 9.1%	2 9.5%

Outcome Measures

1. Primary Outcome

Title	Change in Short-term Virologic Response
Description	Relative potencies of two monotherapy regimens (TDF alone vs. ABC alone) compared to the dual NRTI regimen of TDF+ABC as assessed by the short-term virologic response. (Change in HIV RNA copies/mL at baseline and day 7 for monotherapy, baseline and day 49 for dual therapy.)
Time Frame	49 days

Outcome Measure Data

Analysis Population Description

Median monotherapy decay slopes compared to dual therapy decay slopes after addition of second antiviral agent.

Arm/Group Title	Tenofovir	Abacavir
Arm/Group Description	Monotherapy tenofovir (300mg) for 7 days followed by a 35-day washout period then 7 days of TDF + ABC dual therapy	Monotherapy abacavir (600mg) for 7 days followed by a 35-day washout period then 7 days of ABC + TDF dual therapy
Measure Participants	10	11
monotherapy	-.11	-.15
dual therapy (combined TDF+ABC)	-.16	-.16

2. Primary Outcome

Title	Compare the Plasma Data of the Two Monotherapy Regimens to the Dual NRTI Regimen
Description	At day 49 of Sequence 2 a 24-hour post dose plasma sample should be collected and processed. All 7 samples from the sparse PK (time 0, 30-min, 1-hr, 2-hr, 3-hr, 6-hr and 24-hr post dose) should be sent overnight to appropriate off-site lab for analysis. Since the patient is on dual therapy and the each drug is measured in separate labs each PBMC samples should be split at each time-point with half of the samples shipped to Gilead and half shipped to USC (two separate shipments). ALL plasma samples should be sent to USC. Since samples have to be split we will need to collect double the blood for the intracellular (PBMC) PK: Blood volume (PBMC-plasma): 40 mL - each draw Blood volume (plasma only): 3 mL - each draw Blood volume: 169 mL- over 2 days Plasma NRTI and intracellular ddNTP concentrations were measured 7 days after treatment with ABC or TDF alone and were compared to levels obtained after 7 days of treatment with both drugs
Time Frame	49 days

Outcome Measure Data

Analysis Population Description

Plasma NRTI concentrations were measured after 7 days on monotherapy and after 7 days on dual therapy

Arm/Group Title	Tenofovir	Abacavir
Arm/Group Description	Monotherapy tenofovir (300mg) for 7 days followed by a 35-day washout period then 7 days of TDF + ABC dual therapy	Monotherapy abacavir (600mg) for 7 days followed by a 35-day washout period then 7 days of ABC + TDF dual therapy
Measure Participants	10	11
monotherapy	3.82	12.54
dual therapy	4.09	13.62

3. Secondary Outcome

Title	Evaluate Change in Cellular Regulatory Enzymes Involved With Nucleoside Analogue Transport Across Cell Membranes as Assessed by RT-PCR of Specific mRNA Transcripts
Description	At day 1 and day 63 a PBMC sample for RT-PCR of nucleoside analogue transport enzymes (enzymes for efflux, influx) will be collected. The day 1 specimen should be stored and sent with day 8 PK specimens to USC. Day 63 specimen should be sent to USC after collection and processing. Blood volume: 20 mL Blood volume: 20 mL
Time Frame	Day 1 and Day 63

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Tenofovir	Abacavir
Arm/Group Description	Monotherapy tenofovir (300mg) for 7 days followed by a 35-day washout period then 7 days of TDF + ABC dual therapy	Monotherapy abacavir (600mg) for 7 days followed by a 35-day washout period then 7 days of ABC + TDF dual therapy
Measure Participants	10	11
dGTP concentrations	4026	2464
dATP concentrations	3238	3314

4. Secondary Outcome

Title	Determine Total Number of NRTI-associated Mutations After 7 Days of ABC or TDF Monotherapy or After 7 Days of Dual NRTI Therapy With ABC + TDF
Description	Subjects will be randomized to either TDF or ABC PO route for 7 days, which involves a fixed number of subjects. A sample size of 20 subjects (10 ABC and 10 TDF monotherapy and 20 ABC+TDF dual-therapy in HIV-positive patients). We determined the count of NRTI-associated mutations that emerged after 7 days of ABC or TDF monotherapy or after 7 days of dual NRTI therapy with ABC + TDF.
Time Frame	7 days

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Tenofovir	Abacavir
Arm/Group Description	Monotherapy tenofovir (300mg) for 7 days followed by a 35-day washout period then 7 days of TDF + ABC dual therapy	Monotherapy abacavir (600mg) for 7 days followed by a 35-day washout period then 7 days of ABC + TDF dual therapy
Measure Participants	10	11
Number [mutations]	0	0

5. Secondary Outcome

Title	Compare the Relative Viral Potency of TDF Monotherapy Versus ABC Monotherapy
Description	Eligible patients will be randomized into two monotherapy arms (TDF and ABC) for a short (one week) viral dynamics and pharmacokinetics evaluation to determine their potency. After a one-month washout period, all patients will start a dual-therapy of ABC+TDF. Viral dynamics and pharmacokinetics of the dual-therapy will be evaluated during the first week of the treatment. EFV will be added to the regimen after one week of the dual-therapy administered. Relative potencies of two monotherapy regimens (TDF alone vs. ABC alone) assessed by the short-term virologic response. (Change in HIV RNA copies/mL at baseline and day 7 for monotherapy)
Time Frame	Baseline and day 7

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Tenofovir	Abacavir
Arm/Group Description	Monotherapy tenofovir (300mg) for 7 days followed by a 35-day washout period then 7 days of TDF + ABC dual therapy	Monotherapy abacavir (600mg) for 7 days followed by a 35-day washout period then 7 days of ABC + TDF dual therapy
Measure Participants	10	11
Median (Full Range) [log(10) copies/mL per day]	-0.11	-0.15

6. Primary Outcome

Title	Compare the Intracellular Pharmacokinetic (PK) Data of the Two Monotherapy Regimens to the Dual NRTI Regimen
Description	At day 49 of Sequence 2 a 24-hour post dose intracellular (PBMC) should be collected and processed. All 7 samples from the sparse PK (time 0, 30-min, 1-hr, 2-hr, 3-hr, 6-hr and 24-hr post dose) should be sent overnight to appropriate off-site lab for analysis. Since the patient is on dual therapy and the each drug is measured in separate labs each PBMC samples should be split at each time-point with half of the samples shipped to Gilead and half shipped to USC (two separate shipments). ALL intracellular (PBMC) samples should be sent to USC. Since samples have to be split we will need to collect double the blood for the intracellular (PBMC) PK: Blood volume (PBMC-plasma): 40 mL - each draw Blood volume (plasma only): 3 mL - each draw Blood volume: 169 mL- over 2 days Intracellular ddNTP concentrations were measured after 7 days on monotherapy and after 7 days on dual therapy
Time Frame	49 days

Outcome Measure Data

Analysis Population Description

Intracellular ddNTP concentrations were measured after 7 days on monotherapy and after 7 days on dual therapy

Arm/Group Title	Tenofovir	Abacavir
Arm/Group Description	Monotherapy tenofovir (300mg) for 7 days followed by a 35-day washout period then 7 days of TDF + ABC dual therapy	Monotherapy abacavir (600mg) for 7 days followed by a 35-day washout period then 7 days of ABC + TDF dual therapy
Measure Participants	10	11
monotherapy	49.3	72.2
dual therapy	108.1	80.9

Adverse Events

Time Frame	14 months
Arm/Group Title	Tenofovir		Abacavir
Arm/Group Description	Monotherapy tenofovir (300mg) for 7 days followed by a 35-day washout period then 7 days of ABC + TDF dual therapy		Monotherapy abacavir (600mg) for 7 days followed by a 35-day washout period then 7 days of ABC + TDF dual therapy
All Cause Mortality
	Tenofovir		Abacavir
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	0/10 (0%)		0/11 (0%)
Serious Adverse Events
	Tenofovir		Abacavir
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	0/10 (0%)		0/11 (0%)
Other (Not Including Serious) Adverse Events
	Tenofovir		Abacavir
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	0/10 (0%)		0/11 (0%)

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.